This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Donald F. Klein, MD

Arch Gen Psychiatry. 1974;31(5):735-741.

Abstract
The professional and legal status of the package insert needs radical revision. Currently this insert is considered part of drug labeling and must be approved by the Food and Drug Administration (FDA). The actions of the FDA are primarily regulatory with regard to industry, sales, and communications.

However, the package insert has achieved, in many physicians' minds, an unwarranted quasi-legal status so that an indication or dosage that is not specifically recommended becomes, by default, experimental or investigational and may open the physician to a charge of malpractice.

An alternative format for the package insert is described, with use of a pharmacotherapeutic monograph as a model. A partial example of such a procedure with chlorpromazine is offered.

Author Affiliations
From the Department of Psychiatry, Research, and Evaluation, Long Island Jewish-Hillside Medical Center, Glen Oaks, NY.

Footnotes
Accepted for publication June 13, 1974.

Reprint requests to the Department of Psychiatry, Research, and Evaluation, Long Island Jewish-Hillside Medical Center, PO Box 38, Glen Oaks, NY 11004 (Dr. Klein).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?